Abstract
Platelet activation, causing formation of platelet aggregates, plays a major role in occlusive thrombus formation which may induce ischemic cardiovascular diseases. Thromboxane A2 (TXA2) is an extremely potent vasoconstricting and platelet-aggregating agent so that it is important to search for a new type of thromboxane synthase inhibitor combined with thromboxane receptor antagonism (TxRA/TxSI) dual blocker with high potency and less side effects. On the basis of the structures of some known TxRA/TxSI dual blockers, we used 3D molecular modelling to search for pharmacophores for the dual blockers. Drug Dev. Res. 39:197–200. © 1997 Wiley-Liss, Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
